Katrine Fuglsang

Katrine Fuglsang

Auto-generated profile, based on publicly available information

Katrine Fuglsang

Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
GTGry Assam Taarnhøj
Gry Assam Taarnhøj
ICIb Jarle Christensen
Ib Jarle Christensen
HLHenrik Lajer
Henrik Lajer
KFKatrine Fuglsang
Katrine Fuglsang
MJMette Moustgaard Jeppesen
Mette Moustgaard Jeppesen
CHClaus Kim Høgdall
Claus Kim Høgdall

1 March 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
PJPernille Tine Jensen
Pernille Tine Jensen
TSTine H. Schnack
Tine H. Schnack
LFLigita P. Frøding
Ligita P. Frøding
SBSigne F. Bjørn
Signe F. Bjørn
HLHenrik Lajer
Henrik Lajer
CHClaus Kim Høgdall
Claus Kim Høgdall

11 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
SBSara Bønløkke
Sara Bønløkke
MSMagnus Stougaard
Magnus Stougaard
BSBoe Sorensen
Boe Sorensen
BBBerit Booth Booth
Berit Booth Booth
Estrid HøgdallEstrid Høgdall
Estrid Høgdall
TSTorben Steiniche
Torben Steiniche
Circulating cell-free HPV DNA (ccfHPV DNA) may serve as a marker for cervical cancer. In this study, we used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in plasma from patients with HPV16- or HPV18-associated cervical cancer. Blood samples from 60 patients diagnosed with cervical cancer (FIGO IA1-IVA) at Aarhus or Odense University Hospital (June 2018 to March 2020) were collected prior to treatment, and patients were subdivided into an early stage (n = 30) and a late-stage subgroup (n = 30) according to disease stage. Furthermore, blood samples from eight women with HPV16- or 18-associated premalignant conditions (CIN3), and 15 healthy controls were collected. ddPCR was used to analyze plasma from all participants. ccfHPV DNA was detected in 19 late-stage patients (63.33%), 3 early stage patients (10.00%), and none of the CIN3 patients or controls. Quantitative evaluation showed significant correlations between ccfHPV DNA level and stage, tumor score, and tumor size. Thus, our results indicate that ccfHPV DNA may not be a useful marker for early detection of cervical cancer. However, for patients with advanced stage cervical cancer, ccfHPV DNA level represents a promising tool to establish tumor burden, making it useful for establishing treatment response and monitoring the disease.

1 October 2010 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
KFKatrine Fuglsang
Katrine Fuglsang
LPLone Kjeld Petersen
Lone Kjeld Petersen
Cesarean section in women with placenta previa is associated with the risk of heavy bleeding. We describe a new method where local hemostasis is obtained by applying a hemostatic fleece directly onto the lower uterine segment. During a 2‐year period women undergoing cesarean section due to placenta previa were treated with this hemostatic fleece if they had ongoing bleeding during the surgical procedure despite routine treatment. Data were obtained retrospectively from the hospital records. Fifteen patients were treated by 15 different surgeons. No patients required reoperation. Three patients required blood transfusion due to anemia. No patients were readmitted to the hospital due to endometritis. We conclude that the application of a hemostatic fleece directly onto the bleeding surfaces in patients with post‐cesarean bleeding due to placenta previa is technically unproblematic. The results suggest that this procedure should be considered in case of bleeding after delivery in women with placenta previa.

28 April 2022 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
AHAnne Hammer
Anne Hammer
JBJan Blaakaer
Jan Blaakaer
MKMaurits N. C. de Koning
Maurits N. C. de Koning
TSTorben Steiniche
Torben Steiniche
EMElse Mejlgaard
Else Mejlgaard
PGPatti E. Gravitt
Patti E. Gravitt
Introduction: Understanding whether human papillomavirus (HPV) may establish latency in the uterine cervix is important. A better understanding of HPV natural history is useful for clinical counseling of women attending screening and to accurately inform health prevention strategies such as screening and HPV vaccination. We evaluated the extent of latent HPV infections in older women with a history of abnormal cytology.Material and Methods: We conducted a cross‐sectional study in Aarhus, Denmark, from March 2013 through April 2015. Women were enrolled if they underwent cervical amputation or total hysterectomy because of benign disease. Prior to surgery, women completed a questionnaire and a cervical smear was collected for HPV testing and morphological assessment. For evaluation of latency (i.e., no evidence of active HPV infection, but HPV detected in the tissue), we selected women with a history of abnormal cervical cytology or histology, as these women were considered at increased risk of harboring a latent infection. Cervical tissue underwent extensive HPV testing using the SPF10‐DEIA‐LipA25 assay.Results: Of 103 women enrolled, 26 were included in this analysis. Median age was 55 years (interquartile range [IQR] 52–65), and most women were postmenopausal and parous. The median number of sexual partners over the lifetime was six (IQR 3–10), and 85% reported no recent new sexual partner. Five women (19.2%) had evidence of active infection at the time of surgery, and 19 underwent latency evaluation. Of these, a latent infection was detected in 11 (57.9%), with HPV16 being the most prevalent type (50%). Nearly 80% (n = 14) of the 18 women with a history of previous low‐grade or high‐grade cytology with no treatment had an active or latent HPV infection, with latent infections predominating. HPV was detected in two of the six women with a history of high‐grade cytology and subsequent excisional treatment, both as latent infections.Conclusions: HPV can be detected in cervical tissue specimens without any evidence of an active HPV infection, indicative of a latent, immunologically controlled infection. Modeling studies should consider including a latent state in their model when estimating the appropriate age to stop screening and when evaluating the impact of HPV vaccination.

21 February 2022 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
SSSarah Mejer Sørensen
Sarah Mejer Sørensen
CHClaus Høgdall
Claus Høgdall
BMBerit Jul Mosgaard
Berit Jul Mosgaard
MDMaya Isabella Riise Dalgaard
Maya Isabella Riise Dalgaard
MJMai Partridge Jensen
Mai Partridge Jensen
TSTine Henrichsen Schnack
Tine Henrichsen Schnack
Introduction: It is debated whether women with FIGO (International Federation of Gynecology and Obstetrics) Stage IV epithelial ovarian cancer should be offered primary debulking surgery (PDS) or interval debulking surgery (IDS). Furthermore, the impact of complete resection of intra‐abdominal disease (R0) despite their extra‐abdominal metastases is questioned. The objective of this study was to investigate the impact of intra‐abdominal residual tumor, Stage IVA vs IVB, the localization and number of metastases defining Stage IV disease on overall survival (OS) comparing PDS and IDS in FIGO Stage IV epithelial ovarian cancer.Material and Methods: We included 2091 women registered with Stage IIIC–IV ovarian cancer in the Danish Gynecological Cancer Database during 2009–2016. The impact of residual tumor was evaluated using univariate and multivariate analyses.Results: In total, 681 patients had stage IV disease, of whom 26% underwent PDS, 38% IDS, and 36% chemotherapy only. Overall survival for PDS and IDS were similar. Patients achieving R0 at PDS showed a tendency towards a higher OS than patients achieving R0 at IDS, though the difference was non‐significant. In women with Stage IVA and IVB disease there was a survival benefit in achieving R0 both when treated with PDS and IDS. Women with Stage IVB disease treated with chemotherapy only had a significantly lower OS than patients achieving R0 at both PDS and IDS. Malignant pleural effusion and having five metastatic sites compared with having one was associated with a poorer OS.Conclusions: Our study shows similar OS in patients with Stage IV disease treated with IDS compared with PDS. Complete intra‐abdominal tumor resection improves the prognosis in both PDS and IDS in Stage IV ovarian cancer. Malignant pleural effusion seems to be a negative prognostic factor and should have more focus in future studies.